ZNF778

Summary

ZNF778 (zinc finger protein 778, HGNC:26479) is a protein-coding gene on chromosome 16q24.3, encoding Zinc finger protein 778 (Q96MU6). May be involved in transcriptional regulation.

The protein encoded by this gene is a member of the krueppel C2H2-type zinc-finger protein family, and it contains one KRAB domain and eighteen C2H2-type zinc fingers. This gene is a candidate gene for autism and variable cognitive impairment in the 16q24.3 microdeletion syndrome. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 197320 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 229 total — 1 likely-pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001201407

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26479
Approved symbol	ZNF778
Name	zinc finger protein 778
Location	16q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ31875
Ensembl gene	ENSG00000170100
Ensembl biotype	protein_coding
Entrez	197320

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000306502, ENST00000433976, ENST00000564906, ENST00000565414, ENST00000565877, ENST00000567651, ENST00000620195, ENST00000924205

RefSeq mRNA: 3 — MANE Select: NM_001201407 NM_001201407, NM_001378881, NM_182531

CCDS: CCDS45550, CCDS73928

Canonical transcript exons

ENST00000433976 — 7 exons

Exon	Start	End
ENSE00001176506	89226694	89237141
ENSE00003337626	89222092	89222183
ENSE00003421260	89220997	89221152
ENSE00003490785	89223157	89223283
ENSE00003649919	89224719	89224802
ENSE00003679071	89225555	89225631
ENSE00003738162	89217703	89217910

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 85.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6802 / max 83.6374, expressed in 1769 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155589	8.6802	1769

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	85.19	gold quality
monocyte	CL:0000576	84.29	gold quality
mononuclear cell	CL:0000842	83.97	gold quality
leukocyte	CL:0000738	83.30	gold quality
cortical plate	UBERON:0005343	80.91	gold quality
mucosa of paranasal sinus	UBERON:0005030	80.58	gold quality
secondary oocyte	CL:0000655	80.42	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	80.19	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.28	gold quality
ganglionic eminence	UBERON:0004023	79.24	gold quality
superficial temporal artery	UBERON:0001614	78.72	gold quality
corpus callosum	UBERON:0002336	78.64	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.41	gold quality
granulocyte	CL:0000094	78.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.95	gold quality
cardia of stomach	UBERON:0001162	76.78	gold quality
calcaneal tendon	UBERON:0003701	76.49	gold quality
muscle of leg	UBERON:0001383	76.09	gold quality
islet of Langerhans	UBERON:0000006	76.08	gold quality
vena cava	UBERON:0004087	75.96	gold quality
stromal cell of endometrium	CL:0002255	75.72	gold quality
gastrocnemius	UBERON:0001388	75.72	gold quality
inferior vagus X ganglion	UBERON:0005363	75.60	silver quality
tonsil	UBERON:0002372	75.57	gold quality
muscle organ	UBERON:0001630	74.92	gold quality
ventricular zone	UBERON:0003053	74.90	gold quality
substantia nigra pars reticulata	UBERON:0001966	74.82	gold quality
postcentral gyrus	UBERON:0002581	74.79	gold quality
pericardium	UBERON:0002407	74.66	gold quality
saphenous vein	UBERON:0007318	74.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.50

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

28 targeting ZNF778, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-767-3P	98.61	67.69	1192
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-1178-3P	98.57	67.09	890
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-676-5P	98.49	68.87	1492
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-224-5P	98.33	70.12	1256
HSA-MIR-4289	98.26	66.90	810
HSA-MIR-6865-3P	97.54	64.67	684
HSA-MIR-6831-3P	97.49	69.29	505
HSA-MIR-6839-5P	96.74	68.29	1088
HSA-MIR-378J	96.44	66.20	1020
HSA-MIR-342-3P	96.44	67.48	1344

Literature-anchored findings (GeneRIF, showing 2)

• ZNF778 is a candidate gene for autism and variable cognitive impairment in the novel 16q24.3 microdeletion syndrome. (PMID:19920853)
• ZNF768 links oncogenic RAS to cellular senescence. (PMID:34404770)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp763	ENSMUSG00000067430
rattus_norvegicus	Zfp763	ENSRNOG00000057416

Paralogs (62): ZNF582 (ENSG00000018869), ZNF264 (ENSG00000083844), ZNF343 (ENSG00000088876), ZNF684 (ENSG00000117010), ZNF133 (ENSG00000125846), ZNF557 (ENSG00000130544), ZNF337 (ENSG00000130684), ZNF20 (ENSG00000132010), ZFP37 (ENSG00000136866), ZNF614 (ENSG00000142556), KRBOX4 (ENSG00000147121), ZNF599 (ENSG00000153896), ZNF19 (ENSG00000157429), ZNF589 (ENSG00000164048), PRDM9 (ENSG00000164256), ZNF180 (ENSG00000167384), ZNF558 (ENSG00000167785), ZNF35 (ENSG00000169981), ZNF439 (ENSG00000171291), ZNF440 (ENSG00000171295), ZNF556 (ENSG00000172000), ZNF554 (ENSG00000172006), ZNF596 (ENSG00000172748), ZNF80 (ENSG00000174255), ZNF266 (ENSG00000174652), ZNF25 (ENSG00000175395), ZNF77 (ENSG00000175691), ZNF169 (ENSG00000175787), ZNF404 (ENSG00000176222), ZNF491 (ENSG00000177599), ZNF620 (ENSG00000177842), ZNF619 (ENSG00000177873), ZNF875 (ENSG00000181666), ZNF329 (ENSG00000181894), ZFP90 (ENSG00000184939), ZNF566 (ENSG00000186017), ZNF529 (ENSG00000186020), ZNF749 (ENSG00000186230), ZNF555 (ENSG00000186300), ZNF70 (ENSG00000187792)

Protein

Protein identifiers

Zinc finger protein 778 — Q96MU6 (reviewed: Q96MU6)

All UniProt accessions (4): Q96MU6, A0A0A0MSW5, H3BSD4, H3BUU4

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96MU6-1	1	yes
Q96MU6-2	2

RefSeq proteins (3): NP_001188336, NP_001365810, NP_872337 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050826	Krueppel_C2H2_ZnFinger	Family

Pfam: PF00096, PF01352

UniProt features (27 total): zinc finger region 18, sequence conflict 4, splice variant 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MU6-F1	63.83	0.27

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway
R-HSA-9843940	Regulation of endogenous retroelements by KRAB-ZFP proteins

MSigDB gene sets: 51 (showing top): NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON, GOCC_NUCLEAR_BODY, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, DACH1_TARGET_GENES, ELF2_TARGET_GENES, GLI1_TARGET_GENES, RBM34_TARGET_GENES, SKIL_TARGET_GENES, ZFHX3_TARGET_GENES, ZNF507_TARGET_GENES, ZNF585B_TARGET_GENES, MIR6873_3P, GSE10325_BCELL_VS_LUPUS_BCELL_UP

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Regulation of endogenous retroelements	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

456 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF778	ANKRD11	Q6UB99	622
ZNF778	CPNE7	Q9UBL6	566
ZNF778	S4R434	S4R434	544
ZNF778	ZNF385B	Q569K4	541
ZNF778	SLC22A31	A6NKX4	506
ZNF778	CDH15	P55291	467
ZNF778	TSHZ3	Q63HK5	451
ZNF778	TRAPPC2L	Q9UL33	447
ZNF778	SPG7	Q9UQ90	424
ZNF778	GATA4	P43694	399
ZNF778	PABPN1L	A6NDY0	360
ZNF778	LRRIQ3	A6PVS8	349
ZNF778	KLHDC4	Q8TBB5	348
ZNF778	TTK	P33981	334
ZNF778	ZCCHC14	Q8WYQ9	325

IntAct

9 interactions, top by confidence:

A	B	Type	Score
ZNF778	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-7	ZNF778	psi-mi:“MI:0915”(physical association)	0.560
VCP	VCF1	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
LTBP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
EFEMP1	ZNF316	psi-mi:“MI:0914”(association)	0.350
ZNF778	LRP4	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): KRTAP10-7 (Two-hybrid), ZNF778 (Affinity Capture-MS), ZNF778 (Affinity Capture-RNA), ZNF778 (Two-hybrid), SNX16 (Affinity Capture-MS), ZNF778 (Affinity Capture-MS), SV2B (Affinity Capture-MS), LRP4 (Affinity Capture-MS), ZNF778 (Affinity Capture-MS), ZNF778 (Affinity Capture-MS)

ESM2 similar proteins: A0JPL0, A6NK53, E7ETH6, E9Q8G5, O14628, P21506, P51508, Q09FC8, Q13360, Q2M218, Q2M3X9, Q2VY69, Q3KQV3, Q3SY52, Q4R882, Q5HY98, Q5REN4, Q5RES8, Q68DI1, Q6NX49, Q6P280, Q6PG37, Q6V9R5, Q6ZMW2, Q7Z340, Q86XU0, Q8IYI8, Q8N587, Q8N720, Q8N859, Q8NB42, Q8NDW4, Q8NEK5, Q8WXB4, Q96MR9, Q96MU6, Q96NG8, Q96NJ3, Q96SR6, Q9BR84

Diamond homologs: A0JPK3, A8MT65, C9JN71, E9QAG8, G3X9G7, O75820, P16373, P16374, P16415, P17017, P17024, P17025, P51815, P52737, Q08AG5, Q08ER8, Q0D2J5, Q15973, Q2M218, Q3KP31, Q3V080, Q494X3, Q4R4C7, Q5MYW4, Q5R9F0, Q5R9S5, Q5REI6, Q5REK1, Q68EA5, Q6P560, Q6P5C7, Q6ZQV5, Q7L945, Q86T29, Q8BGV5, Q8C6P8, Q8IYI8, Q8IZC7, Q8N7K0, Q8N972

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

229 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	191
Likely benign	24
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2665007	Single allele	Likely pathogenic

SpliceAI

1164 predictions. Top by Δscore:

Variant	Effect	Δscore
16:89217857:A:T	donor_gain	1.0000
16:89217907:GCTG:G	donor_gain	1.0000
16:89222087:TTTA:T	acceptor_loss	1.0000
16:89222088:TTA:T	acceptor_loss	1.0000
16:89222089:TA:T	acceptor_loss	1.0000
16:89222091:GGA:G	acceptor_gain	1.0000
16:89223279:AGTAG:A	donor_loss	1.0000
16:89223280:GTAG:G	donor_gain	1.0000
16:89223280:GTAGG:G	donor_loss	1.0000
16:89223282:AGG:A	donor_loss	1.0000
16:89223284:G:GC	donor_loss	1.0000
16:89223285:T:A	donor_loss	1.0000
16:89224714:TACA:T	acceptor_loss	1.0000
16:89224716:CAG:C	acceptor_loss	1.0000
16:89224717:A:AG	acceptor_gain	1.0000
16:89224717:A:T	acceptor_loss	1.0000
16:89224718:G:GG	acceptor_gain	1.0000
16:89224801:AGGTA:A	donor_loss	1.0000
16:89224804:T:A	donor_loss	1.0000
16:89225553:A:AG	acceptor_gain	1.0000
16:89225554:G:GG	acceptor_gain	1.0000
16:89225554:GA:G	acceptor_gain	1.0000
16:89225628:GACG:G	donor_gain	1.0000
16:89225632:G:GG	donor_gain	1.0000
16:89217911:G:GG	donor_gain	0.9900
16:89217949:G:GT	donor_gain	0.9900
16:89222088:TTAGG:T	acceptor_gain	0.9900
16:89222089:TAGG:T	acceptor_gain	0.9900
16:89222090:A:AG	acceptor_gain	0.9900
16:89222090:AGGA:A	acceptor_gain	0.9900

AlphaMissense

4982 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:89227576:T:C	F402L	0.999
16:89227578:C:A	F402L	0.999
16:89227578:C:G	F402L	0.999
16:89227660:T:C	F430L	0.999
16:89227662:C:A	F430L	0.999
16:89227662:C:G	F430L	0.999
16:89227744:T:C	F458L	0.999
16:89227746:C:A	F458L	0.999
16:89227746:C:G	F458L	0.999
16:89227828:T:C	F486L	0.999
16:89227830:C:A	F486L	0.999
16:89227830:C:G	F486L	0.999
16:89228248:T:C	F626L	0.999
16:89228250:T:A	F626L	0.999
16:89228250:T:G	F626L	0.999
16:89227617:C:A	H415Q	0.998
16:89227617:C:G	H415Q	0.998
16:89227689:T:A	H439Q	0.998
16:89227689:T:G	H439Q	0.998
16:89227857:C:A	H495Q	0.998
16:89227857:C:G	H495Q	0.998
16:89227862:G:C	R497P	0.998
16:89228080:T:C	F570L	0.998
16:89228082:C:A	F570L	0.998
16:89228082:C:G	F570L	0.998
16:89228164:T:C	F598L	0.998
16:89228166:C:A	F598L	0.998
16:89228166:C:G	F598L	0.998
16:89228183:T:C	L604P	0.998
16:89228267:T:C	L632P	0.998

dbSNP variants (sampled 300 via entrez): RS1000037757 (16:89211977 G>A,T), RS1000041781 (16:89201760 G>C), RS1000054584 (16:89208727 A>G,T), RS1000101379 (16:89236953 A>C), RS1000162116 (16:89223595 A>G,T), RS1000222221 (16:89226301 G>C), RS1000276846 (16:89223485 C>T), RS1000279390 (16:89205809 T>C), RS1000316189 (16:89216238 G>A), RS1000335906 (16:89216645 C>T), RS1000450686 (16:89220143 C>T), RS1000549005 (16:89222945 G>A), RS1000579940 (16:89222841 A>C,G), RS1000673017 (16:89217601 T>C), RS1000749275 (16:89200455 G>A,C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:148050

GenCC curated gene-disease

Mondo (3): KBG syndrome (MONDO:0007846), microcephaly (MONDO:0001149), obesity disorder (MONDO:0011122)

Orphanet (3): KBG syndrome (Orphanet:2332), Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly
HP:0001513	Obesity

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004632_49	Lymphocyte percentage of white cells	7.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007993	lymphocyte percentage of leukocytes

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
C537015	KBG syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
Tobacco Smoke Pollution	increases expression	2
aristolochic acid I	increases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
trichostatin A	affects expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
ferrous chloride	decreases expression	1
nickel sulfate	increases expression	1
abrine	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Copper	affects binding, decreases expression	1
Disulfiram	decreases expression, affects binding	1
Estradiol	increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tretinoin	increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06465641	PHASE4	RECRUITING	Methylphenidate in KBG Syndrome: N-of-1 Series
NCT00076362	PHASE4	COMPLETED	Pediatric Hypothalamic Obesity
NCT00079547	PHASE4	COMPLETED	The Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063	PHASE4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT00134303	PHASE4	COMPLETED	Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936	PHASE4	COMPLETED	The Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962	PHASE4	COMPLETED	Comparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360	PHASE4	COMPLETED	The Effect of Xenical on Weight and Risk Factors
NCT00176306	PHASE4	COMPLETED	Levofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450	PHASE4	COMPLETED	Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504	PHASE4	COMPLETED	Oral Contraceptives in the Metabolic Syndrome
NCT00229229	PHASE4	TERMINATED	Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988	PHASE4	COMPLETED	A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589	PHASE4	COMPLETED	Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873	PHASE4	COMPLETED	Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857	PHASE4	TERMINATED	A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146	PHASE4	COMPLETED	Optimizing Body Composition for Function in Older Adults
NCT00319202	PHASE4	TERMINATED	Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912	PHASE4	UNKNOWN	Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287	PHASE4	COMPLETED	Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054	PHASE4	COMPLETED	Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637	PHASE4	COMPLETED	Diet, Obesity and Genes (DiOGenes)
NCT00415688	PHASE4	COMPLETED	Lifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641	PHASE4	COMPLETED	Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
NCT00440375	PHASE4	COMPLETED	Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00453557	PHASE4	COMPLETED	Mechanism of Growth Hormone Effects on Adipose Tissue
NCT00456885	PHASE4	COMPLETED	The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
NCT00463112	PHASE4	COMPLETED	Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
NCT00512187	PHASE4	COMPLETED	Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00516919	PHASE4	COMPLETED	Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00522470	PHASE4	COMPLETED	Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
NCT00537810	PHASE4	COMPLETED	Treatment of Binge Eating in Obese Patients in Primary Care
NCT00538486	PHASE4	COMPLETED	A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
NCT00584389	PHASE4	TERMINATED	The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition
NCT00585182	PHASE4	COMPLETED	Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
NCT00632840	PHASE4	COMPLETED	Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00636142	PHASE4	COMPLETED	Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
NCT00675987	PHASE4	COMPLETED	A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
NCT00694811	PHASE4	COMPLETED	Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)
NCT00699413	PHASE4	TERMINATED	Supplements for Controlling Resistance to Insulin